German medical equipment maker Gerresheimer said it expects a wider probe into its accounting practices to impact its 2025 results and has initiated the sale of its U.S. packaging business, Centor, to improve its capital structure.
Germany’s financial regulator, BaFin, announced in September a review of Gerresheimer’s financial statements as of November 30, 2024, citing concerns that the company may have prematurely recognised revenue for some customer contracts.
Sign up here.
… [1514 chars]
Source: Reuters | Published: 2026-02-10T22:57:29Z
Credit: Reuters
